Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.
Jasmeet C. Singh, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS).
Although the field has come a long with developing new treatment options for patients with breast cancers that overexpress HER2, Singh notes that there is still room for improvement. One possibility for the future is that novel agents will be used to develop promising combinations to further improve pathologic complete response (pCR) rates and overall response rates.
There have been exciting pCR data in triple-negative disease showing that the addition of immunotherapy improves pCRs. Singh says it may also be possible to study how surgery can be avoided in some patients with HER2-positive disease.
Learn more about the presentation from 2019 SABCS:https://www.targetedonc.com/conference/sabcs-2019
<< View more resources and information regarding breast cancer
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
February 12th 2025Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.
Read More